巴瑞替尼在胶原抗体诱导性关节炎小鼠模型中的镇痛作用特征研究
该研究在胶原抗体诱导性关节炎(CAIA)小鼠模型中评估巴瑞替尼的镇痛作用,并与依那西普及AAK1抑制剂LP-922761比较。结果显示巴瑞替尼在炎症消退后的晚期仍能减轻痛样行为,而依那西普晚期无效;巴瑞替尼还减少骨丢失、滑膜神经支配及STAT3磷酸化,并抑制背根神经节AAK1信号。
要点
- 巴瑞替尼减轻CAIA关节炎症,其镇痛效应在依那西普无效的晚期最为明显。
- 早期和晚期给予巴瑞替尼均减少CAIA诱导的骨丢失、滑膜神经支配及踝关节和DRG基线STAT3磷酸化。
- 仅晚期给予巴瑞替尼即可减少痛样行为和滑膜神经过度支配,依那西普无此效果。
核心结论
- 数据提示巴瑞替尼不仅作用于免疫细胞,还通过抑制两条与慢性疼痛相关的信号通路作用于神经元和胶质细胞,从而产生镇痛效应。
研究设计与样本
- 在胶原抗体诱导性关节炎(CAIA)小鼠模型中检查巴瑞替尼、依那西普(肿瘤坏死因子抑制剂)和LP-922761(衔接蛋白2相关激酶1(AAK1)抑制剂)对痛样行为的影响。
- 检查晚期低度炎症阶段组织样本以评估治疗效果。
- 进行背根神经节(DRG)细胞体外实验,评估巴瑞替尼对神经元兴奋性和细胞形态的影响。
主要发现
- 巴瑞替尼减轻CAIA诱导的关节炎症,但其镇痛效应在依那西普无效的晚期最为明显。
- 早期和晚期给予巴瑞替尼均显著减少CAIA诱导的骨丢失、滑膜神经支配及踝关节和DRG基线STAT3磷酸化。
- 与依那西普不同,仅在晚期给予巴瑞替尼即可有效减少痛样行为和滑膜神经过度支配。
- 巴瑞替尼在体外调节胶质细胞形态和神经元兴奋性。
- 巴瑞替尼抑制DRG中AAK1信号,阻断AAK1激酶活性在CAIA模型中产生镇痛效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Many rheumatoid arthritis (RA) patients continue to experience persistent pain even after successful management of joint inflammation. Clinical data indicate that RA patients treated with the JAK inhibitor baricitinib consistently achieve pain relief that cannot be entirely attributed to its anti-inflammatory effects. In this study, we investigated the antinociceptive properties of baricitinib using the collagen antibody-induced arthritis (CAIA) model in which mechanical hypersensitivity persists long after resolution of joint inflammation. METHODS: The effects of baricitinib, etanercept (tumour necrosis factor inhibitor), and LP-922761 (adaptor protein-2 (AP2) associated kinase 1 (AAK1) inhibitor) on pain-like behaviour in CAIA mice were examined. Tissue samples from the late, low-grade inflammatory phase were examined for the effect of the treatments. Additionally, in vitro experiments using dorsal root ganglion (DRG) cells were conducted to assess baricitinib's influence on neuronal excitability and cell morphology. RESULTS: Baricitinib reduced CAIA-induced joint inflammation, but its antinociceptive effects were most pronounced during the late phase when etanercept was ineffective. Administering baricitinib both early and late significantly decreased CAIA-induced bone loss, synovial innervation, and baseline STAT3 phosphorylation in ankle joints and DRGs. Unlike etanercept, baricitinib effectively reduced pain-like behaviour and synovial hyperinnervation when administered exclusively in the late phase. Additionally, baricitinib modulated glial cell morphology and neuronal excitability in vitro. Notably, it inhibited AAK1 signalling in DRGs, with AAK1 kinase activity blockade providing an antinociceptive effect in the CAIA model. CONCLUSIONS: Our data suggests that baricitinib has antinociceptive effects by targeting not only immune cells but also neurons and glia cells via inhibition of 2 signalling pathways linked to chronic pain.
引用
- Simon N, Rudjito R, Moll L, et al. Characterisation of the antinociceptive effect of baricitinib in the collagen antibody-induced arthritis mouse model. Ann Rheum Dis. 2025. PMID: 39924372. doi:10.1016/j.ard.2025.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。